Welcome to our dedicated page for Prophase Labs SEC filings (Ticker: PRPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProPhase Labs, Inc. (PRPH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. ProPhase is a biotech, genomics, and consumer health company, and its filings offer detailed information on diagnostics programs, genomics initiatives, consumer products, financing arrangements, and governance matters.
Investors can review current and periodic reports such as Forms 10-K and 10-Q (when available) for discussions of business operations, risk factors, and financial statements. Form 8-K filings are particularly active for PRPH and capture material events including the 1-for-10 reverse stock split approved and implemented in late 2025, at-the-market equity sales agreements, senior secured convertible notes and warrants described in the S-1 registration statement, and updates on legal matters and lease forbearance arrangements. Our AI tools highlight the key points in these filings, such as the rationale for the reverse split, the structure of financing instruments, and the implications of special meeting votes.
For those analyzing capital structure and dilution, the S-1 registration statement filed in October 2025 details the terms of senior secured convertible notes, associated warrants, and registration rights for resale of common stock. AI summaries can help clarify conversion mechanics, floor price concepts, warrant terms, and potential issuance scenarios, without requiring readers to parse every technical clause.
This page also surfaces proxy materials like the definitive proxy statement for the November 2025 special meeting, where stockholders voted on digital asset charter amendments, digital treasury shares, tokenized issuance authority, and stock split and share authorization proposals. Our AI analysis can outline what each proposal authorizes and how it may affect governance, treasury strategy, and future capital actions.
As new filings are posted to EDGAR, they are updated here in near real time. Users can quickly locate 8-Ks on financial results, legal proceedings, or strategic LOIs, as well as registration statements and other key documents. The combination of official SEC text and AI-generated explanations helps investors, analysts, and researchers understand how ProPhase’s diagnostics, genomics, consumer health businesses, and financing activities are reflected in its regulatory record.
ProPhase Labs (Nasdaq: PRPH) filed an 8-K (Item 3.01 & 7.01) disclosing it remains non-compliant with Nasdaq Listing Rule 5550(a)(2) after its shares closed below $1.00 for 30 consecutive trading days. Nasdaq granted a second 180-day extension, moving the cure deadline to December 22 2025. To regain compliance, PRPH must record a closing bid price of at least $1.00 for 10 consecutive business days and receive staff confirmation. Failure to do so will trigger a delisting notice and trading suspension, with only a non-staying appeal available. The company states it is otherwise compliant with all other listing standards and is “actively monitoring” its stock price while evaluating options. A related press release was furnished as Exhibit 99.1.
ProPhase Labs (Nasdaq:PRPH) filed a routine Form 8-K disclosing the appointment of Carolina Abenante, Esq. as an independent director effective June 20, 2025. She immediately joins the Nominating & Corporate Governance Committee and becomes Chair of the Compensation Committee; the Board also intends to add her to the Audit Committee after July 19, 2025, pending shareholder approval. Abenante, 55, is considered independent and financially literate under Nasdaq and SEC rules and brings tax, finance and legal expertise from prior executive roles at NYIAX and other AdTech firms. Director compensation matches existing non-employee terms: $48,000 annual cash retainer plus participation in the Director’s Equity Plan. The company reported no related-party transactions or family relationships.
ProPhase Labs (NASDAQ:PRPH) filed its 2025 Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled for July 18, 2025 at 4:00 p.m. ET in Lynbrook, NY.
Stockholders will vote on four routine items:
- Proposal 1: Elect four director nominees to serve until the 2026 meeting.
- Proposal 2: Ratify Fruci & Associates II, PLLC as independent auditor for fiscal 2025.
- Proposal 3: Advisory Say-on-Pay vote on 2024 executive compensation.
- Proposal 4: Advisory vote on the frequency of future Say-on-Pay votes.
The record date is June 20, 2025; only shareholders of record at that close of business may vote. The proxy materials and the company’s 2024 Form 10-K are available at www.proxyvote.com. Holders may vote by proxy in advance or in person. No contested matters, major transactions, or material changes are disclosed.